Bacterial conjunctivitis.
8-Methoxyfluoroquinolone antimicrobial
Moxifloxacin is a 4th generation synthetic broad spectrum, fluoroquinolone class of antibacterial drug. It has activity against a wide range of gram-positive, gram-negative, anaerobic and atypical bacteria including Mycoplasma pneumoniae. It acts by inhibiting topoisomerase II (DNA gyrase) and topoisomerase IV which are necessary for bacterial DNA replication, transcription & repair.
One drop in the affected eye 3 times a day for 7 days.
Moxifloxacin absorption is decreased when administered with antacids, sucralfate, multivitamins, and multivalent cations (e.g. iron or zinc). Moxifloxacin may enhance the risk of convulsions with NSAIDs and bleeding with warfarin. So concomitant use of Moxifloxacin with them should be avoided.
In patients with a history of hypersensitivity to Moxifloxacin, to other quinolones, or to any of the components in this medication. As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use & institute alternative therapy. Patients should be advised not to wear contact lenses if they have signs & symptoms of bacterial conjunctivitis.
Ocular: Conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, & tearing. Nonocular: fever, increased cough, infection, otitis media, pharyngitis, rash, & rhinitis.
Moxifloxacin Hydrochloride ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when Moxifloxacin hydrochloride ophthalmic solution is administered to a nursing mother.
Keep in a dry place, away from light and heat. Keep out of the reach of children.
.png&w=384&q=75)